Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
Date:5/28/2009

lated expenses, increased R&D activity, and increases in other expenses in an effort to file additional products with the FDA. We filed ten Abbreviated New Drug Applications ("ANDAs") relating to nine products with the FDA during Fiscal 2009 as compared to seven products filed in 2008. This brings our total number of ANDAs pending approval by the FDA to 29 (including four tentative approvals) relating to 25 products. We also submitted ten other various filings with the FDA including those related to new sources on the Active Pharmaceutical Ingredients and alternative manufacturing sites in order to improve our costs on certain products.

We earned a net pre-tax income of $29.5 million in Fiscal 2009, compared to a net pre-tax income of $42.4 million in Fiscal 2008. The reduction in net pre-tax income from last year was primarily due to lower gross profits resulting from price erosion of the products sold, the mix of distributed products sold and the provision for losses expected from the product recalls initiated during the end of Fiscal 2009 and beginning of Fiscal 2010. Net income decreased to $20.5 million during Fiscal 2009 from net income of $35.4 million during the Fiscal 2008.

Mr. Movens stated, "On March 11, 2009 the FDA began an inspection as a follow-up to the October, 2008 Warning Letter. This inspection covers all of the Company's quality and production systems. The inspection concluded on May 12, 2009. The FDA investigators provided the Company with a list of their observations on FDA Form 483. The Company has committed to provide a written response to these observations within 30 days. It is unlikely that we will receive any approvals for any new products out of our Detroit facility until the FDA reviews our remediation response and makes a determination of our status. Currently our status remains unchanged. In January 2009 we changed our leadership in both manufacturing and quality control in order to better
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... there are only 24 hours in a day, that doesn’t seem ... time within their busy schedules for exercise and fitness. Fortunately, one ... get in shape. Here are five ways you can reach your ... Up Your Commute , Consider riding a bike or taking the ... daily routine. If you must use your car to get to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... , , BUENOS AIRES, ... Inc., as the recipient of its 2009 Customer Value Leadership ... has deployed an effective strategy to continuously add value to ... in the medical imaging market. , , ...
... BEIJING, Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the ... medical device,company that develops, manufactures and markets advanced,in-vitro diagnostic ... fiscal quarter ended June 30, 2009 ("1Q FY2009"). ... ("FY2009"). , , 1Q FY2009 Highlights, ...
... 1 The Global Biomarker,Market report analyzes the biomarker ... studies the major market drivers, restraints,and opportunities for the ... the macro- and micro-markets with respect to different,geographic regions. ... market data tables and in-depth TOC on biomarker,market. Early ...
... BEIJING, Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Medical ... leading China-based medical device,company that develops, manufactures and markets ... for the fourth,fiscal quarter ("4Q FY2008") and the full ... 4Q FY2008 Highlights, -- ...
... 1 September: The wider use of reperfusion therapy in patients ... Europe. Effective reperfusion therapy in an AMI patient can cut ... by a sudden blockage of a coronary artery, one of ... Effective reperfusion therapy provides a timely and sustainable reopening of ...
... A therapy called cardiac resynchronization can significantly delay the progression ... in the New England Journal of Medicine . ... by 41 percent, the study found. "This shows, for the ... hospitalization for heart failure can be delayed with pacing therapy," ...
Cached Medicine News:Health News:Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award 2Health News:Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award 3Health News:Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award 4Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 2Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 3Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 4Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 5Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 6Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 7Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 8Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 9Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 10Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 11Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 12Health News:China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 13Health News:MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014 2Health News:MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014 3Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 2Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 3Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 4Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 5Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 6Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 7Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 8Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 9Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 10Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 11Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 12Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 13Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 14Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 15Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 16Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 17Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 18Health News:China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 19
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... BOSTON, Nov. 26 Surface Logix, Inc. today announced,that ... an,update of the company,s drug development pipeline at the ... 27-29, 2007 at The,Pierre Hotel in New York City. ... 2007 at 2:50 PM EST., Surface Logix currently ...
... GAITHERSBURG, Md., Nov. 26 MedImmune, Inc. today,announced ... first Phase 1 clinical,trial of CAM- 3001, a ... of the granulocyte-macrophage colony stimulating factor,receptor (GM-CSFR). The ... of single doses of CAM-3001 in patients with ...
Cached Medicine Technology:MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: